Luminary Therapeutics
luminarytx.com
Actively hiring
Health Care
Regenerative Medicine
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Gopher Angels
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 19, 2023
Certified Luminary Therapeutics Announces FDA Clearance of Phase I, IND for a BAFF CAR to Treat Systemic Lupus Erythematosus (SLE) · wric.com
2019
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Gopher Angels Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
We bring cell therapies to patients through innovative point-of-care manufacturing solutions.
Constellation® is an automated cell therapy manufacturing platform that enables scalable, flexible production without therapy redevelopment…
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Overview
The need for effective therapies to lessen relapse – along with the need for rapid and cost-effective manufacturing -- are among the most pressing matters we face. It is not an overstatement to say we’re in need of cell therapy that ultimately doesn’t lead to more treatment.
News
Report
Luminary Therapeutics to Develop Allogeneic CAR T Therapy for Targeting Solid Tumors
Luminary Therapeutics today announced that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to develop a mesothelin chimeri
Read more
Report
Empowered Patient Podcast: Allogeneic Platform Using Gamma Delta Cells in CAR-T Treatment for Solid Tumors with Jeff Liter Luminary Therapeutics
Jeff Liter is the CEO and Founder of Luminary Therapeutics, which is using gamma delta cells in their approach to CART-T cell therapy because of the ability of these cells to infiltrate solid tumors. With a multi-targeting system, Luminary has demonstrate
Read more
Report
Luminary Therapeutics Announces FDA Clearance Of Phase I, IND For A BAFF CAR To Treat Systemic Lupus Erythematosus (SLE)
Luminary Therapeutics Announces FDA Clearance Of Phase I, IND For A BAFF CAR To Treat Systemic Lupus Erythematosus (SLE). Company LogoLuminary Therapeutics Announces FDA Clearance of IND for LMY-920, a Novel BAFF CAR T-Cell Therapy to Treat Systemic Lupus
Read more
Report
Luminary Therapeutics Announces FDA Clearance of Phase I, IND for a BAFF CAR to Treat Systemic Lupus Erythematosus (SLE)
Read more
Report
Cell & Gene Meeting on the Med Company Presentations
Jeff Liter was on Oncology Tube to discuss Luminarys novel allogeneic manufacturing platform, two approved INDs, and their solid tumor program. See the full video here .
Read more
Report
The MIF Invests in Luminary Therapeutics, KAHR, and Telo Therapeutics to Accelerate Novel Therapies for the Treatment of Multiple Myeloma
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced investments in Luminary Therapeutics, a company using advanced receptor design to improve the depth and durability of pat
Read more
Report
gamma-delta-t-therapies.com - Moz DA 19 aged domain
gamma-delta-t-therapies.com ships with Moz DA 19 and 65 referring domains - a rare descriptive .com pickup. Listed at $195.
Read more
Report
Luminary Therapeutics selected as a 2022/2023 Showcase Company in NIH/NCI's investor initiative program
Minneapolis, MN USA Jul 19 2021 /EINPresswire.com/ - Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI's investor initiative program. Luminary Therapeutics is a clinical stage allogeneic cellular therapy company. Its gamma delt
Read more
Report
Show more news